Multiple Myeloma Trial Results
- Thalidomide a Beneficial Option for Elderly Multiple Myeloma Patients
(Posted: 02/12/2008, Updated: 06/01/2009) - Patients aged 75 and over with newly diagnosed multiple myeloma who received the drug thalidomide in addition to standard therapy (melphalan and prednisone) survived longer than patients who received standard therapy plus a placebo, according to clinical trial results presented at the 2007 annual meeting of the American Society of Hematology.
- Double Transplantation of One's Own Stem Cells Is Not Warranted for Multiple Myeloma
(Posted: 02/24/2009) - The addition of a second hematopoietic stem cell transplant procedure using one's own blood cells does not appear warranted in multiple myeloma, according to the Jan. 21, 2009, Journal of the National Cancer Institute.
- Low-dose Steroid Combined with Lenalidomide Prolongs Survival Compared with High-dose Steroid for Multiple Myeloma Treatment
(Posted: 04/04/2007) - Preliminary results from a large, randomized clinical trial for patients with newly diagnosed multiple myeloma, a cancer typically found in bone marrow, has shown that use of a low dose of the steroid dexamethasone (Decadron ®), in combination with lenalidomide (Revlimid ®) is associated with improved survival when compared to a treatment regimen with lenalidomide and a higher, standard dose of dexamethasone.